PEGylated cationic liposome - DNA nanoparticle assembly in cell culture media: pathway effects and clues to enhanced control and transfection efficiency optimization

XII Spanish-Portuguese Conference on Controlled Drug DeliveryCationic Liposome – DNA nanoparticles constitute a promising approach for safe and efficient delivery of genes for therapeutic applications. In order to be used in vivo, these particles can be coated with an inert and hydrophilic polymer, such as polyethylene-glycol (PEG), which improves blood circulation time by providing steric stabilization against removal by the immune system. In this work we study the influence of the initial salt concentration, which controls the electrostatic atraction between cationic liposomes and anionic DNA, on the structure of PEGylated CL–DNA nanoparticles.info:eu-repo/semantics/publishedVersio

Pathway-dependent effects on the formation of bioreducible polycation-DNA polyplexes in saline media

This research is supported by Microfluidic Layer-by-layer Assembly of Cationic Liposome - Nucleic Acid Nanoparticles for Gene Delivery project (032520) co-funded by FCT and the ERDF through COMPETE2020.info:eu-repo/semantics/publishedVersio

Microfluidics for controlled self-assembly of cubosome nanoparticles of tunable size

info:eu-repo/semantics/publishedVersio

Aprendendo a ensinar química : a importância da avaliação na realização de uma oficina didática com professores em formação

Neste trabalho, um grupo de cinco alunos de licenciatura em química, através do Programa Institucional de Bolsa de Iniciação à Docência, explora diversas facetas sobre o ensino de reações químicas em uma escola pública de ensino médio do Nordeste brasileiro. Através de uma oficina didática, em que diversas reações químicas foram executadas para um grupo de estudantes do primeiro ano do ensino médio, os alunos bolsistas desenvolveram atividades de avaliação, qualitativa e quantitativa, sobre o conhecimento dos estudantes, antes e depois da realização da oficina. Os resultados dos instrumentos de avaliação empregados apontam para uma predominância do uso da linguagem cotidiana pelos alunos para explicar as transformações químicas e para um incremento do número de alunos que apresentaram um maior domínio de competências e habilidades relacionadas com o tema em questão

A versatile nanocarrierCubosomes, characterization, and applications

The impact of nanotechnology on the exponential growth of several research areas, particularly nanomedicine, is undeniable. The ability to deliver active molecules to the desired site could significantly improve the efficiency of medical treatments. One of the nanocarriers developed which has drawn researchers’ attention are cubosomes, which are nanosized dispersions of lipid bicontinuous cubic phases in water, consisting of a lipidic interior and aqueous domains folded in a cubic lattice. They stand out due to their ability to incorporate hydrophobic, hydrophilic, and amphiphilic compounds, their tortuous internal configuration that provides a sustained release, and the capacity to protect and safely deliver molecules. Several approaches can be taken to prepare this structure, as well as different lipids like monoolein or phytantriol. This review paper describes the different methods to prepare nanocarriers. As it is known, the physicochemical properties of nanocarriers are very important, as they influence their pharmacokinetics and their ability to incorporate and deliver active molecules. Therefore, an extensive characterization is essential to obtain the desired effect. As a result, we have extensively described the most common techniques to characterize cubosomes, particularly nanocarriers. The exceptional properties of the cubosomes make them suitable to be used in several applications in the biomedical field, from cancer therapeutics to imaging, which will be described. Taking in consideration the outstanding properties of cubosomes, their application in several research fields is envisaged.This study was supported by the Portuguese Foundation for Science and Technology (FCT) under the scope of the strategic funding of UIDB/04469/2020 unit, by Marie Skłodowska Curie grant (MSCA-RISE; FODIAC; 778388) and by European Regional Development Fund (ERDF) through the Competitiveness factors Operational program—Norte 2020, COMPETE and National Funds through the FCT—under the project AgriFood XXI (NORTE- 01-0145-FEDER-000041). J.L.P. acknowledge the Instituto de Salud Carlos III for a “Sara Borrell” grant (CD19/00250), cofounded by European Social Fund (“El FSE invierte en futuro”). C.J.O.F. acknowledge the FCT for the grant SFRH/149/BD/14199/2019.info:eu-repo/semantics/publishedVersio

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049